5-(2-hydroxyethyl)cytidine | 137248-64-7

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 5-(2-hydroxyethyl)cytidine
• 英文别名: 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(2-hydroxyethyl)pyrimidin-2-one
• CAS: 137248-64-7
• 化学式: C₁₁H₁₇N₃O₆
• 分子量: 287.272
• InChiKey: PXHKHCSQQQUDBL-FDDDBJFASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.8
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  149
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-碘乙醇 、 胞苷 以 水 、 乙腈 为溶剂， 反应 24.0h， 以32%的产率得到5-(2-hydroxyethyl)cytidine
  参考文献：
  名称：

  Hassan, M., Bulletin des Societes Chimiques Belges, 1991, vol. 100, # 8, p. 627 - 630

  摘要：

  DOI：

文献信息

• Optimized oncolytic viruses and uses thereof
  申请人：Sator Therapeutics LLC

  公开号：US11253558B2

  公开（公告）日：2022-02-22

  Methods of inhibiting or reducing tumor growth are disclosed. A composition containing at least one selected oncolytic virus is administered within a tumor of a patient. The virus kills cancerous cells and induces a systemic and lasting anti-tumor immunity that is also compatible with other cancer treatments. Also disclosed are methods of creating synthetic viruses for targeting cancerous tumors.

  本研究公开了抑制或减少肿瘤生长的方法。一种含有至少一种精选溶瘤病毒的组合物被注射到患者的肿瘤内。该病毒可杀死癌细胞，诱导全身性持久抗肿瘤免疫力，并可与其他癌症治疗方法相容。此外，还公开了针对癌症肿瘤的合成病毒的制造方法。
• Screening assay for hepatitis C virus antiviral agents
  申请人：——

  公开号：US20030148267A1

  公开（公告）日：2003-08-07

  The invention includes methods of identifying compounds that increase the mutation rate of hepatitis C virus. The invention can be used to screen libraries of test compounds, including both nucleoside analogs and non-nucleoside analogs. The methods include: 1) contacting a test cell with a candidate compound, wherein the test cell contains a nucleic acid molecule comprising an infectious hepatitis C viral genome, a ribozyme, and an inducible promoter operably linked to the first and second nucleotide sequences, the ribozyme being configured to remove a 3′ sequence unnecessary for replication of the infectious hepatitis C viral genome from a transcript initiated by the inducible promote; and 2) the detection of an increase in hepatitis C virus quasispecies produced by the cell in the presence of the candidate compound. Detection of an increase in quasispecies can be accomplished by, e.g., sequencing HCV nucleic acid molecules isolated from the test cell.

  本发明包括鉴定可提高丙型肝炎病毒变异率的化合物的方法。本发明可用于筛选试验化合物库，包括核苷类似物和非核苷类似物。方法包括1）将候选化合物与试验细胞接触，其中试验细胞含有核酸分子，该核酸分子包含传染性丙型肝炎病毒基因组、核糖核酸酶和与第一和第二核苷酸序列可操作连接的可诱导启动子，核糖核酸酶被配置为从由可诱导启动子启动的转录本中移除复制传染性丙型肝炎病毒基因组所必需的 3′序列；2）检测细胞在候选化合物存在下产生的丙型肝炎病毒准种的增加。例如，可通过对从试验细胞中分离出的丙型肝炎病毒核酸分子进行测序来检测准种的增加。
• Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
  申请人：——

  公开号：US20030119764A1

  公开（公告）日：2003-06-26

  The present invention is directed to the identification and use of ribonucleoside analogs to induce the mutation of an RNA virus, including BVDV, HIV and HCV, or a virus which otherwise replicates through an RNA intermediate. The increase in the mutation rate of the virus results in reduced viability of progeny generations of the virus, thereby inhibiting viral replication. In addition to these methods and related compositions, the invention provides methods and combinatorial chemistry libraries for screening ribonucleoside analogs for mutagenic potential.

  本发明涉及核糖核苷类似物的鉴定和使用，以诱导 RNA 病毒（包括 BVDV、HIV 和 HCV）或以其他方式通过 RNA 中间体复制的病毒发生变异。病毒变异率的增加会导致病毒后代的存活率降低，从而抑制病毒复制。除了这些方法和相关组合物之外，本发明还提供了筛选核糖核苷类似物诱变潜力的方法和组合化学文库。
• Mutagenesis methods using ribavirin and/or RNA replicases
  申请人：Coia Gregory

  公开号：US20050266453A1

  公开（公告）日：2005-12-01

  The use of RNA-replicases for introducing mutations into and selecting for improved RNA molecules is described. The use of ribavirin, or a derivative/analogue thereof, in methods for introducing one or more mutations during replication or transcription of a target nucleic acid molecule is also described. These methods can be used to screen for nucleic acids, or proteins encoded thereby, with altered or new activity. Also provided are kits comprising ribavirin, or a derivative/analogue thereof, for use in mutagenesis procedures.

  介绍了利用 RNA 复制酶将突变引入 RNA 分子并选择改良 RNA 分子的方法。还介绍了在目标核酸分子的复制或转录过程中使用利巴韦林或其衍生物/类似物引入一种或多种突变的方法。这些方法可用于筛选具有改变的或新的活性的核酸或其编码的蛋白质。还提供了包含利巴韦林或其衍生物/类似物的试剂盒，用于诱变程序。
• In vivo affinity maturation scheme
  申请人：Irving Robert

  公开号：US20060099611A1

  公开（公告）日：2006-05-11

  The present invention relates to the field of evolution of nucleic acids in vivo and provides methods and compositions for introducing diversity into gene products. The present invention allows generation of new sequences that have desirable properties by virtue of high frequency mutation events within a cell. The high frequency mutation of a polynucleotide sequence results in, the production of a large population of new sequence variants. Appropriate selection and/or screening permits identification and isolation of mutant forms of the polynucleotide sequence as well as products resulting from expression of the mutant sequences.

  本发明涉及体内核酸进化领域，提供了将多样性引入基因产物的方法和组合物。本发明可通过细胞内的高频突变事件产生具有理想特性的新序列。多核苷酸序列的高频突变会产生大量的新序列变体。适当的选择和/或筛选可以鉴定和分离多核苷酸序列的突变形式以及突变序列的表达产物。